<?xml version="1.0" encoding="utf-8" ?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/" xmlns="http://purl.org/rss/1.0/">




    



<channel rdf:about="http://www.amsterdambiomed.nl/columns/RSS">
  <title>Columns</title>
  <link>http://www.amsterdambiomed.nl</link>

  <description>
    
      
    
  </description>

  

  
            <syn:updatePeriod>daily</syn:updatePeriod>
            <syn:updateFrequency>1</syn:updateFrequency>
            <syn:updateBase>2008-02-01T09:05:07Z</syn:updateBase>
        

  <image rdf:resource="http://www.amsterdambiomed.nl/logo.png"/>

  <items>
    <rdf:Seq>
      
        <rdf:li rdf:resource="http://www.amsterdambiomed.nl/columns/penny-wise"/>
      
      
        <rdf:li rdf:resource="http://www.amsterdambiomed.nl/columns/it-is-business-stupid"/>
      
      
        <rdf:li rdf:resource="http://www.amsterdambiomed.nl/columns/team-transform"/>
      
      
        <rdf:li rdf:resource="http://www.amsterdambiomed.nl/columns/growingup"/>
      
      
        <rdf:li rdf:resource="http://www.amsterdambiomed.nl/columns/let2019s-make-it-happen-here-in-amsterdam"/>
      
    </rdf:Seq>
  </items>

</channel>


  <item rdf:about="http://www.amsterdambiomed.nl/columns/penny-wise">
    <title>Penny-wise!</title>
    <link>http://www.amsterdambiomed.nl/columns/penny-wise</link>
    <description>Recently the topsector plan Life Sciences &amp; Health was published and presented to Minister Verhagen, of the so-called ELI Ministry. The document is an amazing compressed 60-pager, based on months of hard work by the group of experts chaired by Roel Fonville, and summarizes the conclusions after dozens of 1-to-1 meetings, five regional group sessions with dozens of opinion leaders and after having received over 170 (!) memo's, white papers and letters of intent.</description>
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p>The authors argue in their executive summary that the "position of the sector is promising however the road ahead challenging". And that “the quality of health care issue in the Netherlands and elsewhere is facing an immense sense of urgency in the near future that calls for urgent investments in Life Sciences &amp; Health research”. In other words, arguments that still count in a right-wing political climate.</p>
<p>However then comes the surprise. The expert panel argues that innovation funding and pre-seed capital remains necessary in coming years, but at the same time does not ask for firm financial measures. NWO, KNAW, TNO budgets should remain unchanged and on a yearly basis so-called innovation and public-private investment capital of around 50-100 M€ should become available (which is less than was available in recent years).</p>
<p><b>Pound-foolish</b><br />This while there is such an immense gap between what is currently invested and what in fact is necessary in upcoming years. As Alexander Rinnooy Kan of the SER already pointed out in 2009, up to 4 million people in the Netherlands will need health care because of aging, with yearly budgets ranging from 25 billion€ at present to &gt; 40 billion€ around 2040. And while in a European setting this problem is becoming priority nr 1 on the agenda, the topsector team Life Sciences &amp; Health comes with old school solutions and penny-wise but pound-foolish advice.</p>
<p><b>My advice?</b><br />Keep investing in graduate training! Because educating the upcoming generations of scientists is the <i>best investment </i>one can ever make. If a 'tsunami' of health care problems related to for instance aging or an infectious disease overwhelms the West European setting, in the metaphor of thunderstorms, we will need <i>educated </i>and <i>skilled professionals </i>that can take action when necessary.</p>
<p>Keep investing in scientific excellence! Because our national team-leaders in the academic setting that are currently outperforming the international competition for instance in the fields of Neurosciences, Genomics and Clinical Neurology are excellent role-models and the most productive professionals around. Their production is immense since these are the experts that train the new generations of professionals, also those that end up in other parts of the sector such as industry and/or TTO related organizations.</p>
<p>Let’s start <i>open innovation</i> and long-term collaborative research programs between scientists and industrial partners. Let’s start thinking about TTO offices as<i> industry alliance offices</i> where the professionals assist the academic faculty by providing leads and connections to people in industry and to facilitate the industrial acquisition of intellectual property. The industry alliance officers of the future should contact "industry volunteers as endurable partners" who will work directly with the academic faculty to facilitate the transfer of research results to the marketplace so that the public can benefit from these discoveries. Let’s bring the industrials to the academic campus instead of the other way around, and lets start finding real solutions to real problems soon!</p>
<p><i><b>Arjen Brussaard</b></i><br /><i>Professor of Neuro sciences<br />Head of Department, <a class="external-link" href="http://www.cncr.nl">Center for Neurogenomics and Cognitive Research</a><br />Director <a class="external-link" href="http://www.neurosciencecampus-amsterdam.nl">Neuroscience Campus Amsterdam</a>, VU University Medical Center<br />Coordinating director <a class="external-link" href="http://www.enc-network.eu">European Neuroscience Campus Network</a></i> <i><br />Cofounder <a class="external-link" href="http://www.synaptologics.com">Synaptologics</a><br />Managing director <a class="external-link" href="http://www.neurobasic.nl">NeuroBasic PharmaPhenomics</a></i></p>
<p><a class="mail-link" href="mailto:arjen.brussaard@neurosciencecampus-amsterdam.nl?subject=Reactie op column Amsterdambiomed.nl">arjen.brussaard@neurosciencecampus-amsterdam.nl</a></p>]]></content:encoded>
    <dc:publisher>No publisher</dc:publisher>
    <dc:creator>Josje Spinhoven</dc:creator>
    <dc:rights></dc:rights>
    <dc:date>2011-06-21T14:25:00Z</dc:date>
    <dc:type>Page</dc:type>
  </item>


  <item rdf:about="http://www.amsterdambiomed.nl/columns/it-is-business-stupid">
    <title>It’s business stupid</title>
    <link>http://www.amsterdambiomed.nl/columns/it-is-business-stupid</link>
    <description>What is it with the Dutch that they have such difficulty grabbing business opportunities in a changing world? We have the brains, we have the money and the opportunities are plenty. Still, during the last 40 years hardly any company of substantial size has emerged next to the old industry in the AEX.  Oil, food, materials and financial services dominate the landscape. We have left the environmental challenges to environmentalists, rather then building innovative businesses in solar or wind energy to help face them. We have exported our knowledge on agriculture around the world, and now that we can more intelligently engineer crops we let the opportunity pass due to invalid arguments around GMOs. Now that  “kweekersrecht” is being substituted by patent law we complain instead of adapt.</description>
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<p>Healthcare is probably the second biggest business opportunity after sustainable energy. We want to grow old healthy, and we are willing to spend a few bucks on it. And not just in the Netherlands where the market potential is only 1% of the developed world. We invented the microscope, the artificial kidney, bone marrow transplants, and played a prominent role in the improvement of modern imaging techniques. But with the take-over of Organon by Schering Plough and the subsequent take-over of Schering by Merck the outlook for the classical Dutch pharmaceutical industry is bleak. However, new companies are being set up in the healthcare field that could develop into attractive businesses.</p>
<p>Since the discovery of the gas reserves in Groningen, the Netherlands has pumped 211 billion Euros out of the ground, money that should have been wisely spent to strengthen our global competitive position. Since 2005 a fraction of this money finds its way into the life sciences. Through CTMM, BMM, NGI, Parelsnoer and TiPharma, a few hundred million Euros per year are invested in public-private initiatives in the biotechnology sector. One would think that these investments are expected to yield tangible innovations and marketable healthcare products or services. What a shame then that by imposing certain requirements for reimbursement, Dutch law actually excludes innovative healthcare products. So, it turns out that we pay lip service only with our so-called commitment to R&amp;D and life sciences. Because once a product is ready for the market, we’re not willing to pay for it.  If we are really serious about creating a knowledge economy in the Netherlands, and have decided that healthcare should be an integral part of it, which I believe we have, this attitude must change.</p>
<p>Surely that will not be enough. For healthcare innovation really to take root, patients must find their voice and demand only the best; physicians should be stimulated to accept change sooner and learn how to apply innovation faster; companies should bring innovation based on market needs, rather than coincidental research results; and government should break down market entry barriers for evidence-based medical innovations. If we succeed in aligning all market participants, we will create the right environment for a growing healthcare industry.</p>
<p>As to costs, we should accept that an initial incremental increase in healthcare costs is bound to go hand in hand with the adoption of innovation. I am certain that the future will show that it is a small prize to pay for an industry that truly has the ability to shape the knowledge economy that we so much aspire to and that will reward us with the rich dividends of a healthier, more productive and advanced society.</p>
<p><em>Bas van der Baan</em></p>
<p>Director Business Development of <a href="http://www.agendia.com/" target="blank">Agendia</a></p>
<p></p>
]]></content:encoded>
    <dc:publisher>No publisher</dc:publisher>
    <dc:creator>rgeerts</dc:creator>
    <dc:rights></dc:rights>
    <dc:date>2009-11-02T08:40:00Z</dc:date>
    <dc:type>Page</dc:type>
  </item>


  <item rdf:about="http://www.amsterdambiomed.nl/columns/team-transform">
    <title>Team &amp; Transform</title>
    <link>http://www.amsterdambiomed.nl/columns/team-transform</link>
    <description>Technological managers are governing the Life Sciences, ICT and quite some other industries. When these managers were students, they were the smartest ones of their class, excellent in science, learning foreign languages, they don’t need anybody else. I know it so well, well, because I’m one of those.

During scientific conferences we are discussing bluntly and openly with colleagues. We are so used to this attitude that we don’t go easy in accepting knowledge from experts outside our disciplines. The CEO of an organic chemical synthesis company – an expert in chiral chemistry - told me that in his whole career it has never happened that a pharmaceutical researcher from another discipline would ask him for an opinion in his particular field of expertise.</description>
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<p></p>
<p><img class="image-inline" src="Column%20Jos%20van%20weperen.jpg/image_mini" alt="Plaatje Team & Transform" height="128" width="200" /></p>
<p>In Life Sciences the percentage of outsourcing amounts to less than 30 % of the business. The automotive industry is outsourcing 70 % of the business. So I thought let’s go back to the sixties, to the point where the automotive industry had about the same characteristics in terms of percentage of outsourcing and technological governance as the Life Sciences industry has today.</p>
<p>In the sixties the Impalas, Galaxies and Chryslers refused to either stop or turn corners. The Ford Falcon, Plymouth Valiant and Chevy II were selling respectably but their  ‘econo car’ image was boring.</p>
<p>By 1960 Lee Iacocca was named Ford Vice President. He had an engineering background. Iacocca acknowledged Ford’s stodgy image. He set in motion a four-year project team that performed research, market analysis and design. An outside party, JWT, the Chicago based advertising agency, was heavily involved. The idea came up to develop a car from the perspective of the emerging baby-boomer generation. A car unlike their parents’ car. A car with a price of under $ 2500. The requirements included sporty styling. In fact, a poor man’s Ferrari, a ‘personal car’ for younger drivers. After a series of concept cars, the parameters were laid out.</p>
<p>From an engineering perspective the Ford Mustang was heavily based on existing simple components. Much of the chassis, suspension and drivetrain components were derived from the Ford Falcon. The marketing campaign was unprecedented. The sports styling did the rest. The Mustang is the only pony car that has remained in production after four decades. Based on this ‘transforming idea’ the Mustangs pretty much had the sporty sedan market to themselves.</p>
<p>Even though the Plymouth Barracuda was introduced a few weeks earlier than the Mustang, it was obviously a mere facelift on the Valiant compact and only 88,039 were sold in 1964. The Mustang has sold 680,989 cars in the same period, which broke all records for new model introductions. Other pony cars followed, the Chevrolet Camaro in 1966, The AMC Javelin in 1968.  In fact, the automotive market changed from an engineering-dominated market to a business-driven one. Outsourcing, cooperation and comakership started from this time on.</p>
<p>Nowadays we would describe the Ford Mustang as radical innovation. The engineers had the wisdom to give space to Life Style experts, designers and advertisers from internal and external sources. We would view the Barracuda as incremental innovation, a gradual increase from a technical device to more design. The Camaro and Javelin are followers. We must be aware that a high level of uncertainty is a hallmark of the radical innovation associated with the Ford Mustang. The most critical factor being the high uncertainty levels associated with the market. Hence, it’s not only Iacocca, Henry Ford II himself approved the concept and the budget.</p>
<p>In my opinion, this history provides us with some clues on how to handle main issues in innovation in Life Sciences and ICT. The answers to questions like ‘what do our clients really need’ and ‘why should our customers pay for it’ cannot be left to engineers and research staff. Engineers and scientists inventing new stuff and afterwards connecting it to the market will lead to ‘incremental innovation’ and not to transforming ideas.</p>
<p>To achieve radical innovation already in its earliest stages engineers must demand the involvement of competencies and resources, be it fashion designers, hairdressers, advertising people, surgeons, consumers or patients. For real success, build a team first and then come up with transforming ideas. My suggested recipe for taking the market for yourself: Team and Transform. Although you may have been the smartest student, I’m prepared to help you. I’ve learned my lesson. Did you?</p>
<p><em>Jos van Weperen<br /><br /></em>Business head of <a href="http://www.darlingagency.eu/idea">Darlingagency.eu</a> (marketing communication), <a href="http://www.upperbrightside.com/">UpperBrightSide.com</a> (innovation strategy) and managing director of <a title="Science-Please" href="../participants/from-a-to-z/science-please">Science-Please</a> (Life Sciences community)</p>
]]></content:encoded>
    <dc:publisher>No publisher</dc:publisher>
    <dc:creator>rgeerts</dc:creator>
    <dc:rights></dc:rights>
    <dc:date>2009-02-03T11:00:00Z</dc:date>
    <dc:type>Page</dc:type>
  </item>


  <item rdf:about="http://www.amsterdambiomed.nl/columns/growingup">
    <title>Growing Up</title>
    <link>http://www.amsterdambiomed.nl/columns/growingup</link>
    <description>The Spinoza centre for Neuro-imaging, a joint investment in high-quality equipment on the part of a number of research institutions and the Municipality of Amsterdam, was launched at the official residence of the Mayor of Amsterdam on 18 December 2007.

It so happens that life sciences were also discussed at the official residence of Mayor Cohen precisely four years prior to this festive occasion, on 18 December 2003. The question then concerned whether or not knowledge institutions, the business community and the municipality could work together to strengthen the life sciences sector in Amsterdam, and if so how. Fortunately, the answer to this question was affirmative and the launch of the Spinoza centre is a clear indication that the co-operation has proved successful.
</description>
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<p>Over a
period of four years, the Amsterdam BioMed Cluster (this name was still to be
devised in 2003) has grown from a pre-schooler to an adolescent, so to speak.
As is the case with the upbringing of a child, this went in fits and starts. However,
the will <i>and </i>the need to achieve
greater co-operation ultimately proved to be strong enough to overcome any
resistance. Let us count our blessings: knowledge institutions and companies
together give an impulse to the transfer of knowledge, the availability of
financing for companies improves, the life sciences sector of Amsterdam is on the agenda of both the
municipality and the national government, and we have an impressive website.
And of course what I, as a representative of the Chamber of Commerce, feel is
important is the fact that companies in Amsterdam
are doing well. Agendia, AMT and Avantium, to name but three, are stirring
things up on the national and international market.

</p><p>The
adolescent has not yet reached maturity. He still has to gain economic weight.
More companies that are as successful as the three mentioned above, more sales,
and more employment. We have met the conditions for realising this kind of
growth spurt. However, one aspect still needs to be improved: sufficient adequate
business accommodation “in stock” for companies that are just starting out as
well as for companies that have the desire to establish themselves in the area.
There are more than enough possibilities in and around Amsterdam; the main thing now is to transform
these possibilities into building blocks.</p>

<p>I am proud
of the fact that I have been able to contribute to the upbringing of the
Amsterdam BioMed Cluster in my capacity of a representative of the Chamber of
Commerce Amsterdam. I plan to switch jobs as of 1 February 2008. I hope to then
be able to contribute to strengthening the sector of vocational training in the
Zaandam region
and its surroundings, as this is also important. </p>

<p>I wish all
of the partners of the Amsterdam BioMed Cluster a very successful 2008.</p>





<p> <i>Frank de
Graaf<br />Amsterdam</i><i> Chamber of Commerce</i></p>

]]></content:encoded>
    <dc:publisher>No publisher</dc:publisher>
    <dc:creator>Maarten</dc:creator>
    <dc:rights></dc:rights>
    <dc:date>2008-01-25T16:56:48Z</dc:date>
    <dc:type>Page</dc:type>
  </item>


  <item rdf:about="http://www.amsterdambiomed.nl/columns/let2019s-make-it-happen-here-in-amsterdam">
    <title>Let’s make it happen, here in Amsterdam!</title>
    <link>http://www.amsterdambiomed.nl/columns/let2019s-make-it-happen-here-in-amsterdam</link>
    <description>Amsterdam houses two universities and numerous dedicated research institutes. The healthcare related institutions have a long tradition in excellence in research in areas such as oncology, neurosciences, autoimmunity and cardiovascular and infectious diseases. In the field of Life Sciences, one can state: ‘Amsterdam has it all’.</description>
    <content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3>So, let’s wait until something happens…? </h3><p>No, of course not. Here in Amsterdam we very much understand that research leads to innovation. And innovation must be implemented. And implementation must be financed. And finance may lead to business. Easy enough, one might think: let research talk to business: problem solved.<br /><br /></p><h3>Let’s wait again…? Will something happen?</h3><p>No, We don’t think so. In order to succeed, all the steps, from research to business, have to be organised and often facilitated. And although Life Sciences and Biomedical Sciences are global, one primarily needs to organise this on a regional scale, close to the source….the universities that deliver the research results. Why? Because one needs more expertise than only research and business to succeed. One needs top research and top researchers, for sure. One also needs universities and institutions that understand that intellectual property needs to be protected. One needs technology transfer offices capable of valorising the protected IP and setting up new companies. One also needs existing companies that absorb research results and IP. One needs support companies that know all about structuring companies, financing them and build patent portfolios. One needs facilities to host new and innovative companies. And one needs local and regional authorities with guts who will tell the world: ‘Amsterdam has it all’. So, it is not just: be excellent in one thing and ‘it will happen’. No, you need it all: every link in this chain is important and cannot be surpassed.<br /><br />The ‘one has it all’ is not necessarily an advantage. We might have so much that ‘organising it ‘ might be ‘a tough job’, and tougher than one might think. In all regional collaborations we know, the parties have to get acquainted, have to learn about each other’s expertise and then start to collaborate. And this works only when there is a basis of trust en mutual benefit. Unfortunately, this takes time. So let’s wait until that happens?<br /><br />No, Amsterdam, let’s not wait, let’s make it happen! The Amsterdam universities and research institutes are already collaborating, e.g. in the field of technology transfer, in an initiative called ‘I amstarter’. We are not ready, we have just started. The way it works is ‘start doing it’: start to see each other on a regular basis, start to exchange ideas, start to work together and it will happen. But we cannot do it alone, as stated above. We need the Amsterdam BioMed Cluster to ‘organise the region’ and bring all stakeholders together: linking it together to a succesful chain. Participation in Amsterdam BioMed Cluster is free. Please join us in the cluster and let’s make it happen.<br /><br /><i>Ward Mosmuller &amp; Ada Kruisbeek</i><br /><br /></p>]]></content:encoded>
    <dc:publisher>No publisher</dc:publisher>
    <dc:creator>admin</dc:creator>
    <dc:rights></dc:rights>
    <dc:date>2007-10-25T07:22:45Z</dc:date>
    <dc:type>Page</dc:type>
  </item>





</rdf:RDF>

